Genitourinary (Issue 2) | Special Reports

Use of ARN-509 in Prostate Cancer

May 28, 2015

Clinical Articles

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.

Study Illuminates Role of AR-V7 in Carcinogenesis

May 21, 2015

Clinical Articles

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association Meeting by Tyler M. Bauman, BS, is bringing the discussion into focus.

Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC

May 21, 2015

Clinical Articles

Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).

Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPC

May 21, 2015

Clinical Articles

Abiraterone acetate in combination with low-dose prednisone (5 mg) significantly lowered PSA levels with a consistent toxicity profile in men with high-risk nonmetastatic castration-resistant prostate cancer.